Petros Grivas, MD, Oncology, Seattle, WA, Seattle Cancer Care Alliance


OncologySeattle, WA

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Medical Director of Genitourinary Cancers Program

Overview of Dr. Grivas

I am a medical oncologist by training with expertise in genitourinary cancers, such as bladder cancer, prostate cancer and testis cancer. I am dedicated to efficient, personalized and outstanding patient care. I've also had a main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer. In addition, I've spent time giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research.

Education & Training

  • University of MichiganOtherTraining
  • University of Michigan Hospitals and Health Centers
    University of Michigan Hospitals and Health CentersFellowship
  • Drexel University - Hahnemann University Hospital
    Drexel University - Hahnemann University HospitalResidency
  • University of Patras School of MedicineOtherTraining
  • University of Patras School of MedicineMedicalSchool

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2017 - 2020
  • OH State Medical License
    OH State Medical License 2014 - 2019
  • MI State Medical License
    MI State Medical License 2013 - 2017
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Award for Contributions in Cancer Care and Research Athens, Greece, 2018
  • GU Malignancies Pilot Award Case Comprehensive Cancer Center, 2017
  • International Bladder Cancer Network Award IBCN, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations



  • PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • Novel Therapeutic Strategies for Advanced Bladder and Penile Cancer 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Authored Content

  • HER-3 in Colorectal Tumourigenesis: From mRNA Levels Through Protein Status to Clinicopathologic RelationshipsDecember 2018

Press Mentions

  • BAVENCIO® Receives FDA Breakthrough Therapy Designation for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial CarcinomaApril 09, 2020
  • The Blind Leading the Blind: COVID-19, Cancer, and the Need for More DataMarch 25, 2020
  • Growth Factors Play Emerging Role in Bladder CancerMarch 22, 2020
  • Join now to see all

Professional Memberships

Other Languages

  • Greek, Italian

Hospital Affiliations